A308430 logo

CellBion KOSDAQ:A308430 Stock Report

Last Price

₩12.87k

Market Cap

₩164.3b

7D

15.7%

1Y

n/a

Updated

05 Jan, 2025

Data

Company Financials

CellBion Co., Ltd.

KOSDAQ:A308430 Stock Report

Market Cap: ₩164.3b

A308430 Stock Overview

Engages in the research and development of radiopharmaceutical products. More details

A308430 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CellBion Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CellBion
Historical stock prices
Current Share Price₩12,870.00
52 Week High₩29,450.00
52 Week Low₩9,930.00
Beta0
1 Month Change-19.86%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-37.68%

Recent News & Updates

Recent updates

Shareholder Returns

A308430KR PharmaceuticalsKR Market
7D15.7%4.8%2.2%
1Yn/a1.8%-8.3%

Return vs Industry: Insufficient data to determine how A308430 performed against the KR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how A308430 performed against the KR Market.

Price Volatility

Is A308430's price volatile compared to industry and market?
A308430 volatility
A308430 Average Weekly Movement19.6%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.8%
10% least volatile stocks in KR Market3.4%

Stable Share Price: A308430's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A308430's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2010n/aKweon Kimwww.cellbion.co.kr

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications.

CellBion Co., Ltd. Fundamentals Summary

How do CellBion's earnings and revenue compare to its market cap?
A308430 fundamental statistics
Market cap₩164.27b
Earnings (TTM)₩0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A308430 income statement (TTM)
Revenue₩0
Cost of Revenue₩0
Gross Profit₩0
Other Expenses₩0
Earnings₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A308430 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 09:06
End of Day Share Price 2025/01/03 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CellBion Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution